Eluxadoline is a mixed opioid receptor modulator used to treat irritable bowel syndrome with diarrhea (IBS-D). It acts as a μ-opioid receptor agonist, κ-opioid receptor agonist, and δ-opioid receptor antagonist, primarily in the gastrointestinal (GI) tract. This unique activity reduces bowel motility and intestinal secretion, helping to control diarrhea and abdominal pain without causing central opioid effects.
It is administered orally and is minimally absorbed systemically, which limits the risk of CNS-related side effects.
Indications include:
∙ Irritable bowel syndrome with diarrhea (IBS-D) in adults
Parent: Eluxadoline
Parent: Eluxadoline
Parent: Eluxadoline
Parent: Eluxadoline
Parent: Eluxadoline
Parent: Eluxadoline
Parent: Eluxadoline
Parent: Eluxadoline
Parent: Eluxadoline
Parent: Eluxadoline
Eluxadoline Impurities
Impurities in eluxadoline arise from its complex chemical synthesis, involving amide bond formation, stereoselective reactions, and cyclization steps, as well as from degradation due to hydrolysis or oxidation. Given its chronic use in GI disorders, impurity control must comply with ICH Q3A/B, USP, and FDA guidelines.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Eluxadoline is used to treat irritable bowel syndrome with diarrhea (IBS-D) by reducing intestinal contractions and fluid secretion.
It acts on opioid receptors in the gut—agonizing μ- and κ-receptors while antagonizing δ-receptors—resulting in reduced GI motility and pain relief.
It is contraindicated in patients without a gallbladder, those with biliary duct obstruction, pancreatitis, alcohol abuse, or severe liver impairment.
Eluxadoline is generally stable but sensitive to hydrolysis and oxidation. It should be stored in a cool, dry place, protected from light and moisture, in its original container.
